Fmoc-α-Me-Cys(Trt)-OH
Need Assistance?
  • US & Canada:
    +
  • UK: +

Fmoc-α-Me-Cys(Trt)-OH

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

Category
Fmoc-Amino Acids
Catalog number
BAT-008553
CAS number
725728-43-8
Molecular Formula
C38H33NO4S
Molecular Weight
599.7
IUPAC Name
(2R)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-2-methyl-3-tritylsulfanylpropanoic acid
Synonyms
(R)-Fmoc-2-amino-2-methyl-3-tritylsulfanyl-propionic acid
Appearance
White to off-white powder
InChI
InChI=1S/C38H33NO4S/c1-37(35(40)41,39-36(42)43-25-34-32-23-13-11-21-30(32)31-22-12-14-24-33(31)34)26-44-38(27-15-5-2-6-16-27,28-17-7-3-8-18-28)29-19-9-4-10-20-29/h2-24,34H,25-26H2,1H3,(H,39,42)(H,40,41)/t37-/m0/s1
InChI Key
AWLPKAIRGNZKIN-QNGWXLTQSA-N
Canonical SMILES
CC(CSC(C1=CC=CC=C1)(C2=CC=CC=C2)C3=CC=CC=C3)(C(=O)O)NC(=O)OCC4C5=CC=CC=C5C6=CC=CC=C46

Fmoc-α-Me-Cys(Trt)-OH, a protected amino acid derivative commonly employed in peptide synthesis, finds diverse applications in the realm of biochemistry. Here are four key applications:

Peptide Synthesis: A cornerstone of solid-phase peptide synthesis, Fmoc-α-Me-Cys(Trt)-OH plays a crucial role in integrating methylated cysteine residues into peptide sequences. This intricate process enables the creation of peptides endowed with specific structural and functional characteristics. The trityl protection group safeguards the cysteine side chain during chain elongation, thwarting unintended chemical reactions and ensuring precise peptide assembly.

Protein Engineering: Delving into the realm of protein engineering, Fmoc-α-Me-Cys(Trt)-OH emerges as a versatile tool for crafting modified proteins with heightened stability and activity. By introducing methylated cysteine residues, researchers can enhance the protein’s resilience against oxidative damage and aggregation. This molecular manipulation proves invaluable in the production of therapeutic proteins and enzymes, boasting extended shelf life and enhanced efficacy.

Structural Biology: Within the domain of structural biology, Fmoc-α-Me-Cys(Trt)-OH proves indispensable for studies necessitating site-specific protein modifications to unravel structure-function relationships. The methylated cysteine serves as a focal point for incorporating probes or labels for spectroscopic and crystallographic analyses, shedding light on the intricate three-dimensional structures and dynamic behaviors of proteins.

Drug Design: In the arena of drug design, Fmoc-α-Me-Cys(Trt)-OH emerges as a pivotal tool for creating peptide-based drugs or mimetics with diverse pharmacological roles. These modified molecules can act as potent enzyme inhibitors, receptor agonists, or antagonists, offering tailored therapeutic interventions. The structural alterations induced by the methylated cysteine enhance binding affinity and specificity for target proteins, paving the way for the development of novel therapeutics with superior pharmacokinetic profiles.

1. Postsynthetic modification of unprotected peptides via S-tritylation reaction
Masayoshi Mochizuki, Hajime Hibino, Yuji Nishiuchi Org Lett. 2014 Nov 7;16(21):5740-3. doi: 10.1021/ol502773v. Epub 2014 Oct 16.
Tritylation using trityl alcohol (Trt-OH) in 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP) is a convenient and efficient procedure that can offer S-protection of the Cys located in fully unprotected peptides. The procedure simply requires Trt-OH and HFIP to selectively promote S-tritylation in the presence of peptide nucleophilic functionalities.
2. Synthesis of complex head-to-side-chain cyclodepsipeptides
Marta Pelay-Gimeno, Fernando Albericio, Judit Tulla-Puche Nat Protoc. 2016 Oct;11(10):1924-1947. doi: 10.1038/nprot.2016.116. Epub 2016 Sep 15.
Cyclodepsipeptides are cyclic peptides in which at least one amide link on the backbone is replaced with an ester link. These natural products present a high structural diversity that corresponds to a broad range of biological activities. Therefore, they are very promising pharmaceutical candidates. Most of the cyclodepsipeptides have been isolated from marine organisms, but they can also originate from terrestrial sources. Within the family of cyclodepsipeptides, 'head-to-side-chain' cyclodepsipeptides have, in addition to the macrocyclic core closed by the ester bond, an arm terminated with a polyketide moiety or a branched amino acid, which makes their synthesis a challenge. This protocol provides guidelines for the synthesis of 'head-to-side-chain cyclodepsipeptides' and includes-as an example-a detailed procedure for preparing pipecolidepsin A. Pipecolidepsin was chosen because it is a very complex 'head-to-side-chain cyclodepsipeptide' of marine origin that shows cytotoxicity in several human cancer cell lines. The procedure begins with the synthesis of the noncommercial protected amino acids (2R,3R,4R)-2-{[(9H-fluoren-9-yl)methoxy]carbonylamino}-3-hydroxy-4,5-dimethylhexanoic acid (Fmoc-AHDMHA-OH), Alloc-pipecolic-OH, (4R,5R)-5-((((9H-fluoren-9-yl)methoxy)carbonylamino)-4-oxo-4-(tritylamino)butyl)-2,2-dimethyl-1,3-dioxolane-4-carboxylic acid (Fmoc-DADHOHA(acetonide, Trt))-OH and the pseudodipeptide (2R,3R,4R)-3-hydroxy-2,4,6-trimethylheptanoic acid ((HTMHA)-D-Asp(OtBu)-OH). It details the assembly of the depsipeptidic skeleton using a fully solid-phase approach (typically on an amino polystyrene resin coupled to 3-(4-hydroxymethylphenoxy)propionic acid (AB linker)), including the key ester formation step. It concludes by describing the macrocyclization step performed on solid phase, and the global deprotection and cleavage of the cyclodepsipeptide from the resin using a trifluoroacetic acid-H2O-triisopropylsilane (TFA-H2O-TIS; 95:2.5:2.5) cocktail, as well as the final purification by semipreparative HPLC. The entire procedure takes ~2 months to complete.
3. A 'conovenomic' analysis of the milked venom from the mollusk-hunting cone snail Conus textile--the pharmacological importance of post-translational modifications
Zachary L Bergeron, et al. Peptides. 2013 Nov;49:145-58. doi: 10.1016/j.peptides.2013.09.004. Epub 2013 Sep 18.
Cone snail venoms provide a largely untapped source of novel peptide drug leads. To enhance the discovery phase, a detailed comparative proteomic analysis was undertaken on milked venom from the mollusk-hunting cone snail, Conus textile, from three different geographic locations (Hawai'i, American Samoa and Australia's Great Barrier Reef). A novel milked venom conopeptide rich in post-translational modifications was discovered, characterized and named α-conotoxin TxIC. We assign this conopeptide to the 4/7 α-conotoxin family based on the peptide's sequence homology and cDNA pre-propeptide alignment. Pharmacologically, α-conotoxin TxIC demonstrates minimal activity on human acetylcholine receptor models (100 μM, <5% inhibition), compared to its high paralytic potency in invertebrates, PD50 = 34.2 nMol kg(-1). The non-post-translationally modified form, [Pro](2,8)[Glu](16)α-conotoxin TxIC, demonstrates differential selectivity for the α3β2 isoform of the nicotinic acetylcholine receptor with maximal inhibition of 96% and an observed IC50 of 5.4 ± 0.5 μM. Interestingly its comparative PD50 (3.6 μMol kg(-1)) in invertebrates was ~100 fold more than that of the native peptide. Differentiating α-conotoxin TxIC from other α-conotoxins is the high degree of post-translational modification (44% of residues). This includes the incorporation of γ-carboxyglutamic acid, two moieties of 4-trans hydroxyproline, two disulfide bond linkages, and C-terminal amidation. These findings expand upon the known chemical diversity of α-conotoxins and illustrate a potential driver of toxin phyla-selectivity within Conus.
Online Inquiry
Verification code
Inquiry Basket